|
|
|
|
J&J Buys Into Elan's Alzheimer's Program
Johnson & Johnsonand Elan Corp.entered a definitive agreement under which J&J will acquire all of the assets and rights to Elan's Alzheimer's Immunotherapy Program (AIP), through a newly formed company. J&J,...
|
|
|
Pfizer's Chantix Label Gets Black Box Warning
The FDA has mandated that Pfizer update the U.S.product labeling for Chantix, a smoking cessation treatment, with safety information in a black box warning as well as revised warnings and precautions. The updated label, based on post...
|
|
|
Sanofi-Aventis' Multaq Approved by FDA
The FDA has approved Sanofi-Aventis's Multaq (dronedarone) 400 mg tablets.Multaq, an anti-arrhythmic, is the first drug approved in the U.S. to show a clinical benefit to reduce cardiovascular hospitalization in patients with atrial...
|
|
|
Pfizers Sutent Fails Colorectal Cancer Trial
Pfizeris discontinuing the SUN 1122 Phase III trial evaluating Sutent plus FOLFIRI (irinotecan plus infusional 5-fluorouracil and leucovorin) versus FOLFIRI alone for the first-line treatment of metastatic colorectal cancer (CRC).An...
|
|
|
Pfizer’s Sutent Fails Colorectal Cancer Trial
News Item Pfizer is discontinuing the SUN 1122 Phase III trial evaluating Sutent plus FOLFIRI (irinotecan plus infusional 5-fluorouracil and leucovorin) versus FOLFIRI alone for the first-line treatment of metastatic colorectal cancer (CRC)....
|
|
|
Maxygen, Astellas Form Protein JV
Astellas Pharmaand Maxygen will establish a joint venture focused on the discovery, research and development of multiple protein pharmaceutical programs, including Maxygens MAXY-4 program and other early stage programs.As part of the...
|
|
|
Executive Moves: Charles River
Charles River Laboratorieshas made changes within its Research Models and Services (RMS) and Preclinical Services (PCS) and Sales organizations.Real H. Renaud, corporate executive vice president and president, Global RMS, announced he...
|
|
|
Wyeth, Catalyst Enter Factor VIIa R&D Pact
Wyethand Catalyst Biosciences, Inc.have formed an exclusive worldwide collaboration for the discovery, development and commercialization of Factor VIIa products to treat hemophilia and other bleeding conditions. Total payments under the...
|
|
|
Sanofi-Aventis Restructures R&D
Sanofi-Aventisis restructuring its R&D operation and plans to close eight of its 27 R&D sites.The new R&D model, which is expected to be in place by 2013, aims to group researchers in more productive structures,...
|
|
|
Covance Expands Service Capacity
Covance, Inc.is expanding its analytical and stability services facility in Madison, WI, doubling capacity for large-scale, long-term stability and release programs for preclinical, clinical, and chemistry, manufacturing, and control (CMC)...
|
